Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension.

Authors :: Benza, Raymond L.
Barst, Robyn J.
Galie, Nazzareno
Frost, Adaani
Girgis, Reda E.
Highland, Kristin B.
Strange, Charlie
Black, Carol M.
Badesch, David B.
Rubin, Lewis
Fleming, Thomas R.
Naeije, Robert
Source :: CHEST. Oct2008, Vol. 134 Issue 4, p775-782. 8p. 1 Diagram, 3 Charts, 3 Graphs.
Publication Year :: 2008
Abstract: The article presents a study on the health benefits of sitaxsentan on the treatment of pulmonary arterial hypertension. It aimed to provide 1-year observational data with the two endothelin antagonists sitaxsentan and bosentan. There were patients treated with sitaxsentan at 100 mg. who had 96% overall survival and a 34% risk for a clinical worsening event for 1 year.